{"id":352,"date":"2026-11-04T12:51:52","date_gmt":"2026-11-04T07:21:52","guid":{"rendered":"https:\/\/incepbio.com\/blog\/?p=352"},"modified":"2026-11-04T12:58:25","modified_gmt":"2026-11-04T07:28:25","slug":"lims-validation-in-pharma","status":"publish","type":"post","link":"https:\/\/incepbio.com\/blog\/lims-validation-in-pharma\/","title":{"rendered":"LIMS Validation in Pharma: 7 Key Requirements for GMP Compliance"},"content":{"rendered":"\t\t
\n\t\t\t\t
\n \t\t\t

LIMS validation in pharma demonstrates that a Laboratory Information Management System (LIMS) is fit for its intended GMP use. It covers sample management, test methods, specifications, calculations, results, approvals, and ongoing change control. The scope and depth of validation depend on the system's intended use, GMP impact, and documented risk assessment.<\/p>\n\t\t\n<\/div>\n

\n \t\t\t

This guide covers seven key LIMS validation requirements for QA, QC, validation, and IT teams. <\/p>\n\t\t\n<\/div>\n

\n \t\t\t

What Is LIMS Validation in Pharma?<\/strong><\/h2>\n\t\t\n<\/div>\n
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

EU GMP Annex 11<\/a> states that computerised systems used in GMP activities should be validated, while their supporting IT infrastructure should be qualified.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n \t\t\t

A Typical Laboratory Workflow in Scope<\/strong><\/h3>\n\t\t\n<\/div>\n
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

A LIMS usually supports a workflow like the one below. The exact steps, and which of them the LIMS performs, differ by site. The records generated during these steps should support the applicable laboratory record requirements under 21 CFR 211.194(a)<\/a>.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t
\n\n
    \n\n
  1. \n Sample Registration:<\/strong> Record the sample description, source, quantity, lot number or code, and sampling and receipt dates (211.194(a)(1)).\n <\/li>\n\n
  2. \n Test Assignment:<\/strong> Link the sample to the approved test method and applicable specification. Record the method used in accordance with 21 CFR 211.194(a)(2).\n <\/li>\n\n
  3. \n Sample Quantity Used:<\/strong> Record the weight or measure of the sample used for each test, where applicable (21 CFR 211.194(a)(3)).\n <\/li>\n\n
  4. \n Result Entry or Instrument Transfer:<\/strong> Enter results or import them from an instrument or CDS, retaining the complete test data (211.194(a)(4)).\n <\/li>\n\n
  5. \n Calculation:<\/strong> Record calculations, units, and conversion factors used to determine reportable results (211.194(a)(5)).\n <\/li>\n\n
  6. \n Specification Comparison:<\/strong> Compare results against approved specifications and flag results outside limits (211.194(a)(6)).\n <\/li>\n\n
  7. \n Review:<\/strong> Record who performed the test and the second-person review (211.194(a)(7) and (a)(8)).\n <\/li>\n\n <\/ol>\n<\/div>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
    \n \t\t\t

    If the LIMS holds these records or controls these steps, they should be included in the validation scope. Where original data remain in another system, such as a CDS, validate the interface and record linkage too.<\/p>\n\t\t\n<\/div>\n

    \n \t\t\t

    Which Regulations and Guidance Apply?<\/strong><\/h3>\n\t\t\n<\/div>\n
    \n\t\t\t\t\t
    \n\t\t\t\t
    \n\t\t\t\t\t\t\t\t\t
    \n\n
      \n\n
    1. \n EU GMP Annex 11<\/strong> applies to all forms of computerised systems<\/a> used as part of GMP-regulated activities. It expects risk management across the lifecycle, with the extent of validation and data integrity controls based on a justified and documented risk assessment (Principle and clause 1).\n <\/li>\n\n
    2. \n 21 CFR 211.68(b)<\/strong><\/a> requires controls over changes to records, accuracy checks for computer inputs and outputs, and backup data retention. It also provides a specific exception for certain data, such as calculations eliminated through computerisation, where a written program record and appropriate validation data must be maintained.\n <\/li>\n\n
    3. \n 21 CFR 211.194(a)<\/strong><\/a> requires laboratory records to include complete data derived from all tests necessary to assure compliance with established specifications and standards.\n <\/li>\n\n
    4. \n 21 CFR Part 11<\/strong><\/a> applies to electronic records and signatures within its scope. FDA’s scope and application guidance<\/a> takes a narrow view, so document which LIMS records fall under Part 11 instead of assuming all or none.\n <\/li>\n\n
    5. \n ISPE GAMP 5 (Second Edition)<\/strong><\/a> is industry guidance, not a regulation. It supports a risk-based approach.\n <\/li>\n\n <\/ol>\n<\/div>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
      \n\t\t\t\t\t
      \n\t\t\t\t
      \n\t\t\t\t\t\t\t\t\t
      \n\n

      \n The current published EU GMP Annex 11 remains the January 2011 revision. A revised draft was released for consultation in 2025, but the consultation closed on 7 October 2025. The draft should not be treated as an effective requirement. Check the European Commission’s EudraLex Volume 4 page<\/a> for updates.\n <\/p>\n\n<\/div>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

      \n \t\t\t

      7 Key Requirements for LIMS Validation in Pharma<\/strong><\/h2>\n\t\t\n<\/div>\n
      \n \t\t\t

      These seven requirements are a practical framework, not a legally mandated sequence. Each maps to Annex 11 clauses and, where relevant, to US requirements. Scope and evidence depend on intended use, GMP impact, complexity, and documented risk. The examples are illustrations of how to apply the requirements, not regulatory requirements themselves.<\/p>\n\t\t\n<\/div>\n

      \n \t\t\t

      Requirement 1: Define Intended Use and System Scope<\/strong><\/h3>\n\t\t\n<\/div>\n
      \n \t\t\t

      Define the laboratory processes supported by the LIMS and the records it creates. Annex 11 expects user requirements that describe required functions, rest on documented risk assessment and GMP impact, and stay traceable through the lifecycle (clause 4.4). For critical systems, it also expects a system description covering data flows and interfaces (clause 4.3).<\/p>\n\t\t\n<\/div>\n

      \n \t\t\t

      Depending on its intended use, the LIMS may also manage reference standards, reagents, laboratory instrument calibration records, and stability testing. Include these functions in the validation scope where applicable.<\/p>\n\t\t\n<\/div>\n

      \n \t\t\t

      Typical LIMS scope decisions include:<\/p>\n\t\t\n<\/div>\n

      \n\t\t\t\t\t
      \n\t\t\t\t
      \n\t\t\t\t\t\t\t\t\t